Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by JULKUNEN, H. A.
Right arrow Articles by FRIMAN, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JULKUNEN, H. A.
Right arrow Articles by FRIMAN, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

research-article

CONTRACEPTIVE PRACTICE IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

H. A. JULKUNEN*,, R. KAAJA{dagger} and C. FRIMAN*

*Fourth Department of Medicine Helsinki, Finland
{dagger}Department of Obstetrics and Gynaecology, Helsinki University Central Hospital Helsinki, Finland

Correspondence to: Correspondence to H. A. Julkunen, Fourth Department of Medicine, Helsinki University Central Hospital, Unioninkatu 38, SF-00170, Helsinki, Finland

Since there are few data on the use of various birth control methods in systemic lupus erythematosus (SLE), we performed a cross-sectional study of the actual contraceptive practices in a group of 85 Finnish female SLE patients of reproductive age. We also recorded side-effects experienced during the use of oral contraceptives (OCs) and intrauterine devices (IUDs). The use of contraception was lower in SLE patients than in healthy women of the same age (59 vs 77%, P<0.001). Sexually active SLE patients requiring contraception used more often barrier and natural methods (P<0.001) and less often OCs (P<0.05) than the corresponding healthy women. The risk of deep venous thrombosis in SLE patients while using oestrogen-containing OCs was slightly increased (RR 2.3, 95% CI 0.5 to 10.3). Twenty-five (78%) of the 32 patients, who had used progestagen-only contraceptives discontinued them because of side effects, which were mainly gynaecological. Major bleeding or pelvic infection did not occur during the use of IUDs.

KEY WORDS: Systemic lupus erythematosus, Oral contraceptives, Intrauterine devices, Tubal ligation, Barrier and natural contraceptive methods


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Obstet GynecolHome page
H. Browne, S. Manipalviratn, and A. Armstrong
Using an Intrauterine Device in Immunocompromised Women
Obstet. Gynecol., September 1, 2008; 112(3): 667 - 669.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
J-C Piette, A Sbai, and C Frances
Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus
Lupus, February 1, 2002; 11(2): 67 - 70.
[PDF]

Home page
 Postgrad. Med. J.Home page
C C Mok and R W S Wong
Pregnancy in systemic lupus erythematosus
Postgrad. Med. J., March 1, 2001; 77(905): 157 - 165.
[Abstract] [Full Text]

Home page
 LupusHome page
N.K. Arden and T.D. Spector
Oestrogens, Bones Systemic Lupus Erythematosus
Lupus, December 1, 1993; 2(6): 381 - 382.
[PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.